GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

Leukemia

Volumn 27, Issue 2, 2013, Pages 482-485

  Fasan, A ^a   Eder, C ^a   Haferlach, C ^a   Grossmann, V ^a   Kohlmann, A ^a   Dicker, F ^a   Kern, W ^a   Haferlach, T ^a   Schnittger, S ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CEBPA PROTEIN; INTERLEUKIN 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; CANCER PROGNOSIS; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; COHORT ANALYSIS; DOWN REGULATION; EXON; FEMALE; GENE CONTROL; GENETIC RISK; HUMAN; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CCAAT-ENHANCER-BINDING PROTEINS; FEMALE; GATA2 TRANSCRIPTION FACTOR; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84873569964     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.174     Document Type: Letter

References (8)

1. Vicente C, Conchillo A, Garcia-Sanchez MA, Odero MD. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol 2012; 82: 1-17.
2. Zhang SJ, Ma LY, Huang QH, Li G, Gu BW, Gao XD et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci USA 2008; 105: 2076-2081.
3. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43: 1012-1017.
4. Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43: 929-931.
5. Dufour A, Konstandin N, Ksienzyk B, Zellmeier E, Benthaus T, Yaghmaie M et al. High frequency of GATA2 mutations in cytogenetically normal acute myeloid leukemia with biallelic CEBPA mutations identified by exome sequencing. ASH Abstract 2011; 72.
6. Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012; e-pub ahead of print 30 May 2012.
7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
8. Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol Cell Biol 2005; 25: 706-715.